IMBiologics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
51
- Latest Deal Type
-
IPO
- Latest Deal Amount
-
$35.4M
IMBiologics General Information
Description
IMBiologics Corp is a clinical-stage biopharmaceutical company focused on developing differentiated biologic therapies for immunology and inflammation (I&I) and cancer. The company advances next-generation therapeutics using novel target biology, Modern antibody engineering, and proprietary multivalent platform technologies. It is committed to delivering impactful therapies to patients while creating long-term value through scientific innovation and world-wide collaboration. The group's proprietary IM-OpDECon platform enables the development of novel antibody-based therapeutics with differentiated mechanisms of action. It is advancing a portfolio of new programs, including IMB-101/102, IMB-106, IMB-201, and IMB-402, across autoimmune, inflammatory, and immuno-oncology indications.
Contact Information
Website
www.imbiologics.comCorporate Office
- 260, Changnyong-daero
- Yeongtong-gu
- Suwon-si, Gyeonggi-do
- South Korea
Corporate Office
- 260, Changnyong-daero
- Yeongtong-gu
- Suwon-si, Gyeonggi-do
- South Korea
IMBiologics Timeline
IMBiologics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. IPO | 20-Mar-2026 | $35.4M | Completed | Profitable | ||
| 5. Later Stage VC | 14-Oct-2025 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series B) | 24-Jul-2023 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series A) | 01-Aug-2021 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 18-Jan-2021 | $3.65M | $6.98M | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 01-Aug-2020 | $3.33M | $3.33M | Completed | Startup |
IMBiologics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
IMBiologics Patents
IMBiologics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026212457-A1 | Anti-cd40 agonist antibody-based molecule and use thereof | Pending | 02-Apr-2025 | ||
| WO-2026212458-A1 | Antibody specifically binding to hla-e and uses thereof | Pending | 02-Apr-2025 | ||
| WO-2025249974-A1 | Linker conjugated to j chain and j chain complex comprising same | Pending | 30-May-2024 | ||
| AU-2024359197-A1 | Antibody specifically binding to hla-g, and use thereof | Pending | 12-Oct-2023 | ||
| EP-4793288-A1 | Antibody specifically binding to hla-g, and use thereof | Pending | 12-Oct-2023 | C07K16/2833 |
IMBiologics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
IMBiologics FAQs
-
When was IMBiologics founded?
IMBiologics was founded in 2020.
-
Where is IMBiologics headquartered?
IMBiologics is headquartered in Suwon-si, South Korea.
-
What is the size of IMBiologics?
IMBiologics has 51 total employees.
-
What industry is IMBiologics in?
IMBiologics’s primary industry is Drug Discovery.
-
Is IMBiologics a private or public company?
IMBiologics is a Private company.
-
What is the current valuation of IMBiologics?
The current valuation of IMBiologics is .
-
What is IMBiologics’s current revenue?
The current revenue for IMBiologics is .
-
How much funding has IMBiologics raised over time?
IMBiologics has raised $99M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
